Company profile
ZENAS BIOPHARMA, INC.
NASDAQ:ZBIOBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OBEXELIMAB | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05662241 | phase3 | active_not_recruiting | 2023-01-09 | 2025-11-13 | Zenas BioPharma (USA), LLC | A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease |
| NCT05794516 | phase1 | completed | 2023-06-19 | 2024-03-21 | Zenas BioPharma (USA), LLC | A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants |
| NCT05542303 | phase1 | completed | 2022-10-16 | 2023-04-04 | Zenas BioPharma (USA), LLC | A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects |
| NCT06564311 | phase2 | active_not_recruiting | 2024-08-26 | 2025-08-28 | Zenas BioPharma (USA), LLC | A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) |
| NCT06559163 | phase2 | active_not_recruiting | 2024-09-17 | 2026-09-01 | Zenas BioPharma (USA), LLC | A Study of Obexelimab in Patients With Systemic Lupus Erythematosus |
FDA applications (0)
No records yet.